UNLIMITED TURBO LONG - BOSTON SCIENTIFIC | Delayed Deutsche Boerse AG 17:20:22 20/06/2024 BST | ||
| 3.35 EUR | +2.45% |
|
| Current month | +3.48% | ||
| 1 month | +5.48% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 3.35 | +2.45% |
| 19/06/24 | 3.27 | -0.61% |
| 18/06/24 | 3.29 | +0.61% |
| 17/06/24 | 3.27 | -2.39% |
| 14/06/24 | 3.35 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 05:20 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | 
BNP Paribas
|
| WKN | PF4XDH |
| ISIN | DE000PF4XDH8 |
| Date issued | 10/12/2020 |
| Strike | 41.18 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.45 € |
|---|---|
| Lowest since issue | 0.1 € |
| Spread | 0.05 € |
| Spread % | 1.47% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
76.31
USD
Average target price
82
USD
Spread / Average Target
+7.45%
- Stock Market
- Certificates
- Certificat
